John Sharp Insider Profile
4 Followers
John Sharp, VP, Fin & CFO at Ligand Pharma, holds 65.77K shares in Phasebio Pharmaceuticals (Ticker: PHASQ), holds 17.67K shares in Ligand Pharma (Ticker: LGND), holds 3.22K shares in Sequenom (Ticker: SQNM).
John Sharp's Trading History
| PHASQPhasebio Pharmaceuticals | May 24, 2022 | ― | Uninformative Buy | 4.10K | $1.58K | |
| LGNDLigand Pharma | Feb 14, 2014 | VP, Fin & CFO | Informative Sell | 6.50M | $5.46M | |
| SQNMSequenom | ― | ― | ― | $7.69K |
You May Also Like
John Sharp insider profile FAQ
What is the percentage of profitable transactions made by John Sharp?
The percentage of profitable transactions made by John Sharp is 50%.
What is the average return per transaction made by John Sharp?
The average return per transaction made by John Sharp is 6.00%.
What stocks does John Sharp hold?
John Sharp holds: LGND, PHASQ, SQNM stocks.
What was John Sharp’s latest transaction?
John Sharp’s latest transaction was an Uninformative Buy of $4.10K.
What was John Sharp's most profitable transaction?
John Sharp’s most profitable transaction was an Informative Sell of LGND stock on February 14, 2014. The return on the trade was 27.30%.
What is John Sharp's role in Ligand Pharma?
John Sharp's role in Ligand Pharma is VP, Fin & CFO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.
TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.
